The ongoing P-Ib (ARCH) study evaluates the safety, tolerability, impact on muscle damage biomarkers & PK of EDG-5506 (10mg, qd) in 12 adult males with BMD
The results showed a lowered muscle damage biomarker, reduction of CK & fast skeletal muscle troponin I (TNNI2) by 30% & 68% after 2mos., reduced exposure for BMD patients which was consistent with the lower dose of 10mg, shorter half-life associated with a decreased overall muscle mass. The therapy was transient & typically observed in the first few days of dosing
Additionally, patients were more active during 2mos. of dosing with EDG-5506 relative to activity measured in the P-I study, well-tolerated with no discontinuations or dose reductions
Ref: Bussinesswire | Image: Edgewise Therapeutics
